AXIM Share Price Performance
Recent AXIM News & Updates
No updates
AXIM Biotechnologies, Inc. Key Details
Last Reported Earnings
Jun 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.012
- Gross Margin
- 98.12%
- Net Profit Margin
- -4,452.06%
- Debt/Equity Ratio
- -69.2%
AXIM Biotechnologies, Inc. Competitors
About AXIM
- Founded
- 2010
- Employees
- 7
- CEO
- WebsiteView website
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.1%
- 1 Year: 17.7%
- Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading